Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma

24 Jul 2021

Abstract excerpt

Standard chemotherapies for diffuse large B-cell lymphoma (DLBCL), based on the induction of exogenous DNA damage and oxidative stress, are often less effective in the presence of increased MYC and BCL-2 levels, especially in the case of double hit (DH) lymphomas harboring rearrangements of the MYC and BCL-2 oncogenes, which enrich for a patient's population characterized by refractoriness to anthracycline-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Lymphoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34304248
DOI: 10.1038/s41375-021-01347-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphomaPMID 34304248Read ↗

Altered pathways and targeted therapy in double hit lymphomaSemantic proximity Read ↗

Double-hit lymphomas: current paradigms and novel treatment approaches.Semantic proximity Read ↗

Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.Semantic proximity Read ↗

Double hit diffuse large B-cell lymphomas: diagnostic and therapeutic challenges.Semantic proximity Read ↗

Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approachSemantic proximity Read ↗

Molecular background delineates outcome of double protein expressor diffuse large B-cell lymphomaSemantic proximity Read ↗

Double hit lymphoma: from biology to therapeutic implications.Semantic proximity Read ↗

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedSemantic proximity Read ↗

The impact of MYC rearrangements and "double hit" abnormalities in diffuse large B-cell lymphoma.Semantic proximity Read ↗

Double-hit Signature with TP53 Abnormalities Predicts Poor Survival in Patients with Germinal Center Type Diffuse Large B-cell Lymphoma Treated with R-CHOP.Semantic proximity Read ↗

Molecular Subtyping in Diffuse Large B Cell Lymphoma: Closer to an Approach of Precision Therapy.Semantic proximity Read ↗

<i>MYC</i> translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.